Why You Should Invest in Psychedelic ‘Platform Plays’
Ryan Allway
August 25th, 2020
App, Exclusive, Psychedelics, Top Story
The psychedelics industry has experienced tremendous growth over the past year. In addition to regulatory support and decriminalization, many companies have either gone public or raised capital and investors have a growing number of options when it comes to building exposure into their portfolio—including both product and platform opportunities.
Let’s take a look at why you may want to invest in platforms instead of products and how MagicMed Industries is building a promising drug discovery platform for the nascent psychedelics industry.
Why Invest in Platforms?
Many psychedelic companies have focused on developing products, such as functional mushrooms, or undergoing clinical trials to develop therapeutics targeting specific indications. While these companies could see some success, the bigger opportunities often come from companies building diverse platforms that power entire industries.
Ecommerce businesses illustrate the differences between product versus platform business models. Most ecommerce businesses sell their own products, which target a specific customer demographic, but platforms like Amazon.com or Ebay.com have become much larger by providing the underlying marketplace where anyone can sell their products.
Platforms typically generate predictable recurring revenue from licensing or other sale-based fees while diversifying risk across many different markets and products. Since platforms aren’t responsible for actually building any products, they also tend to generate higher profit margins than product-based businesses that have a lot more overhead.
Even better, platforms can still launch their own in-house brands with much higher odds of success. Amazon’s Amazon Basics products are launched based on the success and margins of existing products sold within its marketplace. The company can pick and choose what product verticals to target with a high degree of predictability.
MagicMed’s Psybrary™
MagicMed Industries intends to build a platform, called the Psybrary™, to assist psychedelic companies in the drug discovery process. The molecular derivatives library will be an essential building block from which industry partners can develop new patented products targeting a wide range of indications within the nascent psychedelics industry.
Learn how to become an early-stage investor in MagicMed Industries as it seeks to go public during the first half of next year.
The process starts by taking a natural psychedelic molecule, such as psilocybin, and modifying its structure to create many new derivative molecules. While natural molecules cannot be patented as molecular composition, these new derivative molecules are patentable, making them indispensable when commercializing therapeutics.
Like other platforms, MagicMed’s focus is on providing the building blocks that others can use to be successful in their business. The company will generate high-margin revenue from licensing fees and royalties while benefiting from diversification across a wide range of partners that are each targeting different markets and indications.
MagicMed’s uniquely qualified team includes Dr. Peter Facchini, who has served as Chief Science Officer at several biotech firms, both public and private. He has published more than 160 scientific papers and holds 20 patents in the field, making him a recognized leader in the development of new molecular derivatives.
Looking Ahead
The psychedelics industry is experiencing tremendous growth, creating new opportunities for investors interested in the space. While many companies are focused on developing products or pursuing clinical trials, investors may want to take a closer look at platform plays as an opportunity for higher margin revenue, diversified risk and larger opportunities.
MagicMed Industries has raised $600,000 and plans on a public listing during the first or second quarter of 2021. Management intends to use the proceeds from the public listing to build out its partner base and potentially diversify into consumer goods. If you’re interested in becoming an early stage investor, sign up to learn more with the company’s investor presentation.
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.
Biome Grow (CSE: BIO) wholly owns Highland Grow, an Authorized Licensed Producer in Nova Scotia under the ACMPR, P-209 Inc., a company incorporated under the laws of the Province of Ontario and in the late stages of applying for a license under the ACMPR.
Quadron Cannatech Corporation is a Vancouver based automated extraction and processing solutions company.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
